ConcertAI sings a unicorn tune as the FDA-partnered clinical trials software upstart expands
The crescendo is building at ConcertAI as the artificial intelligence life sciences startup reels in its ensemble to boost clinical study diversity, expand decentralized clinical trials and pile on the real-world data for cancer treatments.
The FDA-partnered upstart raised a $150 million Series C, soaring into unicorn status to a $1.9 billion valuation, to take its tech on a worldwide tour. The current set list of 45 biopharma and contract research organization customers is not enough for the five-year-old Cambridge, MA, company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.